argenx Completes $2.2B Acquisition of Forte Biosciences; 87% of Shares Tendered
FBRX has more than doubled off its 52-week low of $10.11.
Summary
argenx completed its $77-per-share all-cash acquisition of Forte Biosciences on August 27, 2026, after 87.13% of shares were validly tendered. The merger closed without a stockholder vote under Section 251(h), and Forte shares will be delisted from Nasdaq.
Key Events · M&A and Partnerships · FBRX
-
Tender Offer Expired with 87.13% Tendered
19,894,879 shares were validly tendered and not withdrawn by the August 26 expiration, representing 87.13% of outstanding shares including those already owned by argenx affiliates.
-
Merger Consummated Under Section 251(h)
argenx completed the acquisition on August 27, 2026 without a stockholder vote, converting each remaining share into the right to receive $77.00 in cash.
-
Delisting and Deregistration
Forte shares will be delisted from the Nasdaq Capital Market, and argenx intends to terminate Exchange Act registration and suspend reporting obligations as promptly as practicable.
-
Deal Delivers 86% Premium
The $77-per-share all-cash offer represents an 86% premium to Forte's pre-announcement price, valuing the company at approximately $2.2 billion.
Analysis · FBRX · Life Sciences
The argenx acquisition of Forte Biosciences has closed. The tender offer expired on August 26 with 19,894,879 shares validly tendered — 87.13% of outstanding shares — satisfying the minimum tender condition. The merger was consummated on August 27 under Section 251(h) of the DGCL without a stockholder vote, converting each remaining share into the right to receive $77.00 in cash. Shares will be delisted from Nasdaq and Exchange Act registration terminated. This is the final step in a deal that delivers an 86% premium to Forte shareholders and removes the company from public markets.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBRX was trading at $76.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $10.11 to $77.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.